Literature DB >> 8304988

Inhibition of protein kinase C by melittin: antagonism of binding interactions between melittin and the catalytic domain by active-site binding of MgATP.

K R Gravitt1, N E Ward, C A O'Brian.   

Abstract

Melittin inhibits the lipid cofactor-independent activity of protein kinase C (PKC) by directly binding to the catalytic domain in a MgATP-sensitive manner. The catalytic domains of certain PKC isozymes have a consensus sequence for a second nucleotide binding site outside their active site regions. In this report, we show that PKC isozymes containing the second nucleotide binding site motif (alpha, beta) and an isozyme lacking the motif (epsilon) all have MgATP-sensitive binding interactions with melittin. Our results support a mechanism of PKC inhibition by melittin in which active-site binding of MgATP antagonizes binding interactions between PKC and melittin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8304988     DOI: 10.1016/0006-2952(94)90037-x

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  4 in total

1.  Melittin as an epithelial permeability enhancer I: investigation of its mechanism of action in Caco-2 monolayers.

Authors:  Sam Maher; Linda Feighery; David J Brayden; Siobhán McClean
Journal:  Pharm Res       Date:  2007-03-21       Impact factor: 4.580

2.  Melittin as a permeability enhancer II: in vitro investigations in human mucus secreting intestinal monolayers and rat colonic mucosae.

Authors:  Sam Maher; Linda Feighery; David J Brayden; Siobhán McClean
Journal:  Pharm Res       Date:  2007-03-23       Impact factor: 4.580

3.  Pharmacophore modeling, docking and molecular dynamics simulation for identification of novel human protein kinase C beta (PKCβ) inhibitors.

Authors:  Sergiy A Starosyla; Galyna P Volynets; Mykola V Protopopov; Volodymyr G Bdzhola; Denis O Pashevin; Valentyna O Polishchuk; Taisiia O Kozak; Dmytro O Stroi; Victor E Dosenko; Sergiy M Yarmoluk
Journal:  Struct Chem       Date:  2022-10-11       Impact factor: 1.795

Review 4.  Current scenario of peptide-based drugs: the key roles of cationic antitumor and antiviral peptides.

Authors:  Kelly C L Mulder; Loiane A Lima; Vivian J Miranda; Simoni C Dias; Octávio L Franco
Journal:  Front Microbiol       Date:  2013-10-31       Impact factor: 5.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.